IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$33.21
Market Cap
$6.87B
52W High
$45.42
52W Low
$21.86
ADV30
1,456,337
Next earnings
2027-02-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -104,155,000 | -97,246,000 | 760,967,000 | 722,274,000 | 104,022,000 |
| Jun 2026 | 0 | — | -160,323,000 | -153,224,000 | 852,490,000 | 797,798,000 | 117,102,000 |
| Mar 2026 | 0 | — | -159,554,000 | -147,856,000 | 957,014,000 | 902,110,000 | 104,422,000 |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-395,004,000
Investing CF
$-8,000
Financing CF
$596,222,000
CapEx
$-201,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.56
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,995,599,000
Inventory
—
Receivables
$138,000
ST Investments
—
EBIT TTM
$-538,394,000
Pretax Income TTM
$-510,253,000
Interest Exp TTM
—
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | 852,592,000 | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | 707,447,000 | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | 617,757,000 | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | 362,494,000 | -188,193,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-538,217,000
OpCashFlow TTM
—
Assets (Latest)
$852,490,000
Forward EPS
$-2.62
Max Pain — expiry 2026-12-18
max pain strike: $30.00 · spot: $33.17 · call oi: 13,435 · put oi: 1,639Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $7.00B | $78.94 | — |
| IBRX | ImmunityBio, Inc. | $6.66B | $6.26 | — |
| TWST | Twist Bioscience Corp | $7.43B | $112.00 | — |
| KOD | Kodiak Sciences Inc. | $6.33B | $96.80 | — |
| SRRK | Scholar Rock Holding Corp | $5.50B | $45.08 | — |
News headlines (Yahoo Finance, 1h cache)
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
2026-11-11 16:00 · Yahoo
Immunovant (IMVT) Q2 2027 Earnings Call Transcript
2026-11-10 02:03 · Yahoo
Immunovant, Inc. Q2 2027 Earnings Call Summary
2026-11-10 01:55 · Yahoo
Immunovant Stock What Changed After Arthritis Trial Success
2026-11-09 23:23 · Yahoo
What Immunovant (IMVT) Said on Its Q2 Earnings Call
2026-11-09 16:15 · Yahoo
Immunovant surges on trial results, earnings beat
2026-11-09 14:58 · Yahoo
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
2026-11-09 12:00 · Yahoo
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
2026-10-21 11:00 · Yahoo
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
2026-10-20 14:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.